Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026
03/11/2025 18:39
Nov 3 (Reuters) - Maat Pharma SA MAAT.PA: MAAT PHARMA ANNOUNCES POSITIVE PHASE 3 RESULTS EVALUATING XERVYTEG® (MAAT013) IN ACUTE GRAFT-VERSUS-HOST DISEASE SELECTED FOR ORAL PRESENTATION AT ASH CONGRESS 2025 MAAT PHARMA SA - XERVYTEG UNDER EMA REVIEW, DECISION EXPECTED IN H2 2026 Source text: ID:nBw8b0bfga Further company coverage: MAAT.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maat Pharma SA
See all newsBrief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026